Meeting
2016 Gastrointestinal Cancers Symposium
A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma.
Authors
Beate Schultheis
Department of Hematology and Oncology, Marien Hospital Herne, University of Bochum, Herne, Germany
Beate Schultheis , Dirk Strumberg , Jan Kuhlmann , Martin Wolf , Karin Link , Thomas Seufferlein , Joerg Kaufmann , Frank Gebhardt , Nico Bruyniks , Uwe Pelzer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
NCT01808638
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 385)
DOI
10.1200/jco.2016.34.4_suppl.385
Abstract #
385
Poster Bd #
K1
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A single-arm, open-label, phase I study of CPI-613 (Devimistat) in combination with gemcitabine and nab-paclitaxel for patients with locally advanced or metastatic pancreatic adenocarcinoma.
First Author: Angela Tatiana Alistar
Poster
2016 Gastrointestinal Cancers Symposium
A phase Ib dose escalation, safety, and tolerability study of sonidegib in combination with gemcitabine in patients with locally advanced or metastatic pancreatic adenocarcinoma.
First Author: Teresa Macarulla
Poster
2015 ASCO Annual Meeting
A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.
First Author: Aaron James Scott
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Dong-Sheng Zhang